Parcelbio has raised $13 million in seed financing to continue its development of a new class of potent and durable mRNA medicines. The financing will support development of Parcelbio’s proprietary APEXm (Amplified and Prolonged EXpression mRNA) platform and advance its pipeline, including its lead in vivo CAR T program for autoimmune disease.
Arrivent Biopharma Inc. has obtained IND clearance from the FDA for ARR-002 (AV-P138-ADC), an antibody-drug conjugate (ADC) with an initial focus in ovarian and endometrial cancers and broader therapeutic potential across solid tumors. A phase I trial is expected to open in the second half of the year.
A designed chimeric virus induced broadly neutralizing antibodies (bNAbs) against the macaque equivalent of HIV. The strategy works in two steps: first it uses an envelope protein (Env) with a mutation that reduces the glycan shield that makes it invisible to the immune system, and then it exposes the part of the protein most likely to generate these antibodies capable of blocking many variants of the virus. The macaques developed potent and diverse antibodies with this approach, which pave the way for the development of an HIV-1 vaccine.
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry into the cell. This is the first time that antibodies have been shown to bind effectively to two essential viral proteins, creating a dual blockade that prevents infection. Unlike the current vaccine, which is based on an attenuated virus and is not recommended for immunocompromised individuals, these monoclonal antibodies could be used both as a new vaccine approach and as a treatment for the entire population.
Sunrise Oncology (Hong Kong) Ltd. has synthesized new condensed macrocyclic compounds acting as GTPase KRAS inhibitors potentially useful for the treatment of cancer.
Insmed Inc. has identified new cathepsin C (dipeptidyl peptidase I; DPP1) inhibitors potentially useful for the treatment of cancer, inflammatory bowel disease, bronchiectasis, asthma, cystic fibrosis, lupus nephritis, pulmonary hypertension and rheumatoid arthritis.
HK Inno.N Corp. has disclosed new 5-cyclopropylpicolinamide derivatives acting as mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors potentially useful for the treatment of cancer.
Simcere Zaiming Pharmaceutical Co. Ltd. has detailed the discovery and preclinical characterization of ZMS-2195, a multiple-RAS inhibitor designed to prevent both mutant and wild-type forms of KRAS, NRAS and HRAS from binding to the RAS-binding domain (RBD) of RAF, which is required to activate downstream MAPK signaling.
RSS
